GSK raises profit outlook on strong vaccine, HIV drug sales
FY profit forecast raised to 8-10%
*Read moreWed, 29th Jul 2015 15:24
FY profit forecast raised to 8-10%
*Read more(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.
Read more(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.
Read more(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.
Read more(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.
Read moreApril 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.
Read moreApril 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.
Read more(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.
Read moreApril 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.
Read moreApril 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.
Read moreThursday 25 April | |
Aquila European Renewables PLC | Full Year Results |
Argo Blockchain PLC | Full Year Results |
AstraZeneca PLC | Q1 Results |
Barclays PLC | Q1 Results |
Checkit PLC | Full Year Results |
Coca-Cola Europacific Partners PLC | Trading Statement |
Destiny Pharma PLC | Full Year Results |
Dillistone Group PLC | Full Year Results |
Focusrite PLC | Half Year Results |
Gem Diamonds Ltd | Trading Statement |
Hikma Pharmaceuticals PLC | Trading Statement |
Hummingbird Resources PLC | Trading Statement |
Ibstock PLC | Trading Statement |
Inchcape PLC | Trading Statement |
J Sainsbury PLC | Full Year Results |
London Stock Exchange Group PLC | Q1 Results |
Persimmon PLC | Trading Statement |
Pinewood Technologies Group PLC | Full Year Results |
PPHE Hotel Group Ltd | Trading Statement |
PureTech Health PLC | Full Year Results |
Relx PLC | Trading Statement |
Renewi PLC | Trading Statement |
Schroders PLC | Q1 Results |
Skillcast Group PLC | Full Year Results |
Travis Perkins PLC | Trading Statement |
Trifast PLC | Trading Statement |
Unilever PLC | Q1 Results |
WAG Payment Solutions PLC | Trading Statement |
Weir Group PLC | Trading Statement |
WH Smith PLC | Half Year Results |
WPP PLC | Trading Statement |
Zinc Media Group PLC | Full Year Results |
Friday 26 April | |
Facilities by ADF PLC | Full Year Results |
Kingspan Group PLC | Trading Statement |
Loungers PLC | Trading Statement |
NatWest Group PLC | Q1 Results |
Pearson PLC | Trading Statement |
Record PLC | Trading Statement |
Smurfit Kappa Group PLC | Trading Statement |
Taylor Maritime Investments Ltd | Trading Statement |
Monday 29 April | |
Beazley PLC | Trading Statement |
Biome Technologies PLC | Full Year Results |
Christie Group PLC | Full Year Results |
Gresham House Energy Storage Fund PLC | Full Year Results |
Gresham Technologies PLC | Full Year Results |
Jadestone Energy PLC | Full Year Results |
Oxford BioMedica PLC | Full Year Results |
SpaceandPeople PLC | Full Year Results |
Tuesday 30 April | |
Avacta Group PLC | Full Year Results |
Card Factory PLC | Full Year Results |
Capital & Regional PLC | Full Year Results |
Close Brothers Group PLC | Trading Statement |
Coca-Cola HBC AG | Trading Statement |
Elementis PLC | Trading Statement |
essensys PLC | Half Year Results |
Fadel Partners Inc | Full Year Results |
Glencore PLC | Trading Statement |
Hargreaves Lansdown PLC | Trading Statement |
Howden Joinery PLC | Trading Statement |
HSBC Holdings PLC | Q1 Results |
Kelso Group PLC | Full Year Results |
Northcoders Group PLC | Full Year Results |
Phoenix Spree Deutschland Ltd | Full Year Results |
RBG Holdings PLC | Full Year Results |
Rotork PLC | Trading Statement |
Safestore Holdings PLC | Half Year Results |
Shield Therapeutics PLC | Full Year Results |
St James's Place PLC | Trading Statement |
Strip Tinning Holdings PLC | Full Year Results |
Whitbread PLC | Full Year Results |
Wednesday 1 May | |
Computacenter PLC | Trading Statement |
GSK PLC | Q1 Results |
Haleon PLC | Trading Statement |
HSS Hire Group PLC | Full Year Results |
Intelligent Ultrasound Group PLC | Full Year Results |
Maintel Holdings PLC | Full Year Results |
Next PLC | Trading Statement |
Smith & Nephew PLC | Trading Statement |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.
Read more(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.
Read more(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.
Read more(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.
Read more